RoActemra (tocilizumab) licensed for systemic juvenile idiopathic arthritis

The RoActemra dose for children is calculated by weight and given by intravenous infusion every 2 weeks
The RoActemra dose for children is calculated by weight and given by intravenous infusion every 2 weeks

The IL-6-inhibiting antibody tocilizumab (RoActemra) can now be used to treat active systemic juvenile idiopathic arthritis (sJIA) in children 2 years of age and above when the response to NSAIDs and systemic corticosteroids is inadequate. It can be given in combination with methotrexate or as monotherapy when methotrexate is inappropriate or not tolerated.

Clinical study

In the randomised, double-blind TENDER study (n=112), significantly more children treated with tocilizumab achieved the primary endpoint (≥30% reduction in JIA ACR core set score and absence of fever) at week 12 compared with children who received placebo: 85% (64/75) versus 24% (9/37), respectively (p<0.0001).

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases